News / Health

India's Cancer-Drug Ruling Likely to Have Global Impact

People gather at Novartis India headquarters in Mumbai April 1, 2013.
People gather at Novartis India headquarters in Mumbai April 1, 2013.
Jessica Berman
A landmark ruling by India’s high court this week struck down a bid by Swiss drugmaker Novartis to extend patent protection for its cancer drug, Glivec.

The decision is seen as a blow to Western pharmaceutical companies seeking to protect their financial interests.  Experts say it could embolden pharmaceutical companies in other countries hoping to produce generic versions of name-brand medications.  That could mean wider availability of the less expensive drugs throughout the developing world.

India is not the only country manufacturing generic versions of important and popular drugs.  Argentina and the Philippines have passed strict laws limiting the patent protections on name-brand drugs developed by U.S. and European pharmaceutical companies, including medications to treat HIV, the virus that causes AIDS.
 
Patents allow companies that develop a drug to maintain exclusive rights to sell it at a higher price for an extended period of time, in order to recoup their research and development costs.  Western pharmaceutical firms say those returns are essential to their ability to develop new and better medicines.

In the India case, which has been wending its way through the country’s judicial system for 7 years, Novartis failed to convince the high court that it had made changes to Glivec, its widely used leukemia drug, significant enough to warrant extending its patent and exclusive marketing rights.

Tahir Amin is a director of the New York-based Initiative for Medicines, Access and Knowledge, a non-profit organization which works on patent cases to increase access to drugs.  Amin says the India case is likely to have far-reaching implications.

“Globally, I think a number of countries will look at this and say, “Well India stood its ground,” and will also realize that actually if India is standing its ground, even though it has a stronger geopolitical standing and can actually probably stand up to the U.S. and Europe a little bit more, I think other countries will also take notice of this and say, 'This is in our public interest and health interest to adopt patent laws that are somewhat similar,'” said Amin.

India exports some $10 billion worth of generic drugs every year and, along with China, produces about 80 percent of the ingredients that are used in the manufacture of drugs in the United States. India also produces generic versions of many popular drugs.

Novartis and other drug companies say the Indian court ruling may force them to pull their research dollars out of India.

Mark Grayson is a spokesman for the Pharmaceutical Research and Manufacturers of America, or PhRMA, which represents drug manufacturers.
 
“We’re disappointed in this ruling because we believe that this just shows a further deteriorating innovation environment in India," said Grayson.

Generic drug versions can be sold at a fraction of the cost of brand-name drugs.  For example, Glivec can cost a patient around $70,000 a year, while the Indian generic versions costs around $2,500.
 
Grayson believes patients who can afford a drug like Glivec should pay full price.

“We believe we need to find ways to get economies that are growing to pay their fair share for the new medicines and the cost that it takes to develop a lot of this medicine," he said.

Grayson says 95 percent of the patients in India who can't afford Glivec can get it for free through a so-called "compassionate care" program run by Novartis.

But Tahir Amin of Initiatives for Medicine says cancer patients have reported that it has been difficult to obtain those free drugs.

“If you are going to be at the whim of philanthropy, then I think most people are not going to get drugs," he said. "And we’ve seen that in other cases as well, where they say we have access programs and so on and so forth.  But only a certain percentage of the population or countries get it.”

But with drug development costs sometimes topping $1 billion, PhRMA’s Grayson fears that India’s patent ruling and others that may follow could slow the pace at which critically needed new drugs come to market.

You May Like

Koreas Mark 61st Anniversary of War Armistice

Muted observances on both sides of heavily-armed Demilitarized Zone that separates two decades-long enemies More

Judge Declares Washington DC Ban on Public Handguns Unconstitutional

Ruling overturns capital city's prohibition on carrying guns in pubic More

Pricey Hepatitis C Drug Draws Criticism

Activists are using the International AIDS Conference to criticize drug companies for charging high prices for life-saving therapies More

Featured Videos

Your JavaScript is turned off or you have an old version of Adobe's Flash Player. Get the latest Flash player.
Students in Business for Themselvesi
X
Mike O'Sullivan
July 26, 2014 11:04 AM
They're only high school students, but they are making accessories for shoes, fabricating backpacks and doing product photography - all through their own businesses. It's the result of a partnership between a non-profit organization that teaches entrepreneurship and their schools. VOA's Mike O'Sullivan and Deyane Moses met the budding entrepreneurs near Los Angeles.
Video

Video Students in Business for Themselves

They're only high school students, but they are making accessories for shoes, fabricating backpacks and doing product photography - all through their own businesses. It's the result of a partnership between a non-profit organization that teaches entrepreneurship and their schools. VOA's Mike O'Sullivan and Deyane Moses met the budding entrepreneurs near Los Angeles.
Video

Video Astronauts Train in Underwater Lab

In the world’s only underwater laboratory, four U.S. astronauts train for a planned visit to an asteroid. The lab - called Aquarius- is located five kilometers off Key Largo, in southern Florida. Living in close quarters and making excursions only into the surrounding ocean, they try to simulate the daily routine of a crew that will someday travel to collect samples of a rock orbiting far away from earth. VOA’s George Putic has more.
Video

Video Not Even Monks Spared From Thailand’s Junta-Backed Morality Push

With Thailand’s military government firmly in control after May’s bloodless coup, authorities are carrying out plans they say are aimed at restoring discipline, morality and patriotism to all Thais. The measures include a crackdown on illegal gambling, education reforms to promote students’ moral development, and a new 24-hour phone hotline for citizens to report misbehaving monks. Steve Sandford reports from Bangkok.
Video

Video Virtual Program Teaches Farming Skills

In a fast-changing world beset by unpredictable climate conditions, farmers cannot afford to ignore new technology. Researchers in Australia are developing an online virtual world program to share information about climate change and more sustainable farming techniques for sugar cane growers. As VOA's Zlatica Hoke reports, the idea is to create a wider support network for farmers.
Video

Video Airline Expert: Missile will Show Signature on Debris

The debris field from Malaysia Airlines Flight 17 is spread over a 21-kilometer radius in eastern Ukraine. It is expected to take investigators months to sort through the airplane pieces to learn about the missile that brought down the jetliner and who fired it. VOAs Carolyn Presutti explains how this work will be done.
Video

Video Treatment for Childhood Epilepsy Heats up Medical Marijuana Debate

In the United States, marijuana is classed as an illegal drug by the federal government. But nearly half the states have legalized it, to some degree. Proponents say some strains of marijuana might have exceptional health benefits, for treating pain or inflammation in chronic conditions such as cancer, multiple sclerosis and epilepsy. Shelley Schlender reports on a strain of medical marijuana developed in Colorado that is reputed to reduce seizures in childhood epilepsy
Video

Video Airbus Adds Metal 3D Printed Parts to New Jets

By the end of this year, European aircraft manufacturing consortium Airbus plans to deliver the first of its new, extra-wide-body passenger jets, the A350-XWB. Among other technological innovations, the new plane will also incorporate metal parts made in a 3-D printer. VOA's George Putic has more.
Video

Video AIDS Conference Welcomes Exciting Developments in HIV Treatment, Prevention

Significant strides have been made in recent years toward the treatment and prevention of HIV, the virus that causes AIDS. This year, at the International AIDS Conference, the AIDS community welcomed progress on a new pill that may prevent transmission of the deadly virus. VOA’s Anita Powell reports from Melbourne, Australia.
Video

Video IAEA: Iran Turns its Enriched Uranium Into Less Harmful Form

Iran has converted its stockpiles of enriched uranium into a less dangerous form that is more difficult to use for nuclear weapons, according to the United Nations’ Atomic Energy Agency. The move complies with an interim deal reached with Western powers on Iran's nuclear program last year, in exchange for easing of sanctions. Henry Ridgwell reports for VOA from London.

AppleAndroid